The pharmaceutical industry reported a happy half-yearly report and worries after the boom

The pharmaceutical industry is characterized by technology-intensive, high investment, risk and income, and is deeply influenced by the development of the national economy and national policies, and has a strong correlation with the quality of life of the people.
2018, health care reform enters deep water, with opportunities and challenges. The establishment of the National Health Insurance Administration, the continuous promotion of consistent evaluation, the implementation of the new version of medical insurance landing, the proportion of drugs continued control, have brought great impact on the entire pharmaceutical industry. In the first half of the year, driven by policies, the pharmaceutical industry entered a supply-side reform phase, and the industry experienced rapid recovery and growth.
data released by the National Bureau of Statistics show that from January to June this year, the overall economy of the pharmaceutical industry was running smoothly, with the growth rate of the main business revenue 3.4 percentage points higher than the national industrial average and the profit growth rate below the national industrial average of 1.8 percentage points.
the 2018 half-yearly report issued by listed pharmaceutical companies in recent years also confirms the above developments. This "thematic planning" focuses on the A-share listing, as of August 23 to release the semi-annual report of operating income of more than 4.5 billion yuan of 13 pharmaceutical companies (including industry and commerce) data. Of the 13 pharmaceutical companies, the remaining 12, with the exception of Ha Pharmaceutical Group, achieved rapid growth in operating income. In terms of total volume, East China Pharmaceuticals led with revenue of 15.325 billion yuan, while Yan Yan Pharmaceutical led the way with 45.49 percent growth.
The above-mentioned enterprises can achieve very excellent results in the first half of the year, thanks to their active adaptation to the new normal of economic development, closely follow the strategic objectives of their respective companies, according to the industry development situation of the study and analysis, focus on industrial development focus, and constantly strengthen the industrial base, vigorously explore the business map, focus on optimizing the allocation of resources, to consolidate and enhance the management, innovation, investment, construction, operation, service and other aspects of the comprehensive strength. But at the same time, the semi-annual report also revealed a lot of hidden worries, especially sales costs growth too fast, research and development costs accounted for too low, which will seriously hinder the development of innovation in the industry.
In the future, under the overall strategic layout of the state to further promote supply-side structural reform, adhere to innovation and lead development, and implement "Healthy China", the demand for medical and health care of the whole society will continue to rise, the people's health care awareness will continue to strengthen, the demand of the pharmaceutical industry will be stable, and the overall development trend will remain good. However, under the new situation of medical reform brought about by the "three-doctor linkage", the impact of such important policies as consistent evaluation and priority review intensifies the secondary differentiation of pharmaceutical companies, and promotes the industry to remain weak and strong; (Medical Observer)